Innovative technologies are innovations that create a new market and value network and eventually disrupts an existing market and value network, displacing established market leading firms, products and alliances.

Early-stage or angel investing quite often offers potentially very compelling investment returns but it can also be the most risky. As a result, joining RYSE in its diversified approach may be a more suitable solution by piggy backing off its thorough due diligence and screening process in order to source the most interesting investment opportunities whilst benefiting from diversifying the investment risks across a portfolio of potentially high growth companies.

We aim to achieve a high level of diversification and – at the same time – specialisation via our Early Stage Investment Programme.

RYSE Early Stage Investment Programme

This innovative partnership between RYSE Asset Management LLP and DH.L supports early stage digital health businesses within the NHS or other healthcare delivery systems.

The programme leverages public-private relationships to sustain innovation in healthcare. DH.L’s role is to form the bridge between the entrepreneurs and investor, performing the screening and evaluation function.

Funding early stage development

Entrepreneurs consistently face significant financial challenges as they attempt to penetrate the health and care market. These include the costs associated with development, compliance, validation trials and the presentation of data and analysis, as well as the challenges presented by the nature of the digital world itself, being a relatively new industry lacking substantial real-world evidence.

Through the RYSE Early Stage Investment Programme, entrepreneurs are able to access the information they need to raise grants or private funding successfully at each stage of their development.


Typically RYSE seeks to invest with companies at seed stage up to and beyond Series A, to support them in their next phase of growth. Some of these companies may have traction already in the market and may already be revenue generating but are looking to raise between £250,000 and £5,000,000.

Companies that are successful in receiving investment do not have to become part of RYSE’s ecosystem. RYSE does work closely with external accelerator or incubator programmes and is also able to provide office space and full infrastructure with access to experienced and qualified advisers, mentors and sector focussed events to assist in accelerating the growth of the companies and provide hands-on support to their management teams.


RYSE’s objective is to provide investors with capital appreciation from a diversified portfolio of investments across early stage and nascent companies over time.

The offering addresses an investment or funding gap in the market which is largely overlooked by institutional and professional investors alike due to the time involved in undertaking due diligence on a number of early stage companies and their principals or founders. The opportunity enables investors to benefit from a highly diversified portfolio effect without compromising on due diligence.

RYSE’s aim is to source high calibre companies that have developed or are developing a service, product or solution to a commercial, technological or scientific problem in an innovative way.